TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02932423

Intervention type: OTHER
Group type: OTHER
Intervention: Control product E
Description: Plain water

Intervention type: OTHER
Group type: OTHER
Intervention: Control product E
Description: Plain water

Intervention type: OTHER
Group type: OTHER
Intervention: Test product A
Description: Beverage with no sugar but sweetener

Intervention type: OTHER
Group type: OTHER
Intervention: Test product A
Description: Beverage with no sugar but sweetener

Intervention type: OTHER
Group type: OTHER
Intervention: Test product B
Description: Beverage with 22 g/L sugar and sweetener

Intervention type: OTHER
Group type: OTHER
Intervention: Test product B
Description: Beverage with 22 g/L sugar and sweetener
Study: NCT03658148

Intervention type: PROCEDURE
Intervention: Cardiac Surgery with Cardiopulmonary Bypass
Description: Cardiac Surgery with Cardiopulmonary Bypass
Study: NCT02568280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
Study: NCT01350596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alivium®
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
Study: NCT04229914

Intervention type: OTHER
Group type: OTHER
Intervention: stroke patinets
Description: 3-m backwards walk test, timed up and go test, 10 m walk test, Berg BalanceTest, Functional Reach Test
Study: NCT00820599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapien XT™ transcatheter heart valve and delivery system
Study: NCT04596579

Intervention type: BEHAVIORAL
Intervention: Web Based Questionnaire
Description: A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.

Intervention type: BEHAVIORAL
Intervention: Web Based Questionnaire
Description: A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.

Intervention type: BEHAVIORAL
Intervention: Web Based Questionnaire
Description: A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.

Intervention type: BEHAVIORAL
Intervention: Web Based Questionnaire
Description: A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
Study: NCT01282775

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WEB + Environment
Description: Participants receive weekly lessons via the Web along with additional tools for weight loss support

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WEB + Environment
Description: Participants receive weekly lessons via the Web along with additional tools for weight loss support

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WEB + Cash Incentive for Weight Loss
Description: Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
Study: NCT06096129

Intervention type: PROCEDURE
Intervention: Spy PTC
Description: Percutaneous transhepatic cholangioscopy with SpyGlass DS system
Study: NCT03078920

Intervention type: DEVICE
Group type: OTHER
Intervention: Naída CROS
Description: At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
Study: NCT01735929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck Liposuction and Ultrasound Treatment

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Study: NCT01112072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
Study: NCT01101919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
Study: NCT04463264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
Study: NCT00906698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 low (20mg) dosage
Description: Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 low (20mg) dosage
Description: Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 medium (40mg) dosage
Description: Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 medium (40mg) dosage
Description: Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 high (50mg) dosage
Description: Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 high (50mg) dosage
Description: Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine per os 60 mg/m²
Description: Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine per os 80 mg/m²
Description: Patients will receive 80 mg/m² Vinorelbine per os at J22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine i.v. 25 mg/m²
Description: Patients will receive 25 mg/m² of Vinorelbine i.v.
Study: NCT05288101

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proteinex and Enterex DBT Victus Laboratories
Description: The supplement was provided five days per week. Three days a week, the supplement was given at the beginning of the HD session and the patients were instructed to consume it slowly during the next 3 hours. The remaining two days, the supplement was consumed at home and instructed to be consumed between meals. The ONS consisted of one can of polymeric formula (Enterex DBT, Victus Laboratories) and 5.6 g of a protein powder supplement (Proteinex, Victus Laboratories). The final mixture provided 240 kcal, 17 g protein, 8.1 g lipids, 25 g carbohydrates, 4 g dietary fiber, 201 mg sodium, 490 mg calcium, 356 mg phosphorus and 371 mg potassium

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry weight adjustment through BIVA
Description: Those participants with post-dialysis vectors located within the 50 or 75% ellipses, were considered to be in dry weight, so they did not require any fluid removal adjustment. However, participants with vectors outside the 75% ellipse were considered overhydrated or dehydrated and dry weight was adjusted. In these patients, if the vectors fell outside the 75% ellipse but within the 95%, above or below the major axis, the established dry weight was adjusted by 0.5 Kg. If the vectors fell outside the 95% ellipse, the weight was adjusted by 1.0 Kg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry weight adjustment through BIVA
Description: Those participants with post-dialysis vectors located within the 50 or 75% ellipses, were considered to be in dry weight, so they did not require any fluid removal adjustment. However, participants with vectors outside the 75% ellipse were considered overhydrated or dehydrated and dry weight was adjusted. In these patients, if the vectors fell outside the 75% ellipse but within the 95%, above or below the major axis, the established dry weight was adjusted by 0.5 Kg. If the vectors fell outside the 95% ellipse, the weight was adjusted by 1.0 Kg.
Study: NCT02507310

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thermostat
Description: ambient temperature as modified by thermostat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thermostat
Description: ambient temperature as modified by thermostat
Study: NCT04440943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-527
Description: CDX-527 is administered by infusion every 2 weeks
Study: NCT04215341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: A course of breathing retraining delivered by a physiotherapist and practiced by the participant at home.
Study: NCT04669405

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High intensity laser therapy
Description: A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Exercise
Description: A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
Study: NCT01014338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril
Description: 10mg od

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: placebo
Study: NCT03898687

Intervention type: DEVICE
Group type: OTHER
Intervention: SLN Biopsy with Magtrace®/Sentimag®
Description: Identification of SLN by means of Magtrace®/Sentimag® and SPIO-MRI
Study: NCT04127539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong & Steady exercise program
Description: The community-based group exercise program S\&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S\&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S\&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
Study: NCT01599325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous administration of azacitidine 75 mg/m\^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
Study: NCT00483249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Branched Stent-Graft
Description: Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
Study: NCT02987140

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical evaluations
Description: Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical evaluations
Description: Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical evaluations
Description: Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
Study: NCT02374255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GoC intervention
Description: Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
Study: NCT00583531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: Oral, 2 grams TID in sachets for 4 weeks
Study: NCT05226052

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (Floratil 600mg)
Description: PGIC and PGIS assessment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3 capsules of placebo
Description: PGIC and PGIS assessment
Study: NCT01791179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive substance abuse services
Study: NCT01119703

Intervention type: BIOLOGICAL
Intervention: Tetanus & Diphtheria booster vaccine (Td)
Description: Tetanus \& Diphtheria booster vaccine (Td), single intramuscular dose

Intervention type: BIOLOGICAL
Intervention: Tetanus & Diphtheria booster vaccine (Td)
Description: Tetanus \& Diphtheria booster vaccine (Td), single intramuscular dose

Intervention type: BIOLOGICAL
Intervention: TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]
Description: TwinrixTM \[Hepatitis A Inactivated \& Hepatitis B (Recombinant) Vaccine\], intramuscular, two doses of standard three dose regimen (opposite arms)

Intervention type: BIOLOGICAL
Intervention: TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]
Description: TwinrixTM \[Hepatitis A Inactivated \& Hepatitis B (Recombinant) Vaccine\], intramuscular, two doses of standard three dose regimen (opposite arms)
Study: NCT00781898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot naltrexone
Description: Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as Usual (TAU) community treatment provided to the participant
Study: NCT01119703

Intervention type: BIOLOGICAL
Intervention: Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)
Description: Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen

Intervention type: BIOLOGICAL
Intervention: Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)
Description: Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
Study: NCT02828605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Interactive Platform (VIP) Transplant
Study: NCT01972139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation using the Symplicity Renal Denervation System
Description: Subjects randomized to the renal denervation group underwent angiography and renal denervation.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham Renal Denervation
Description: Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.

Intervention type: DEVICE
Group type: OTHER
Intervention: Renal Angiography
Description: Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
Study: NCT02932423

Intervention type: OTHER
Group type: OTHER
Intervention: Test product C
Description: Beverage with 33 g/L sugar and sweetener

Intervention type: OTHER
Group type: OTHER
Intervention: Test product C
Description: Beverage with 33 g/L sugar and sweetener
Study: NCT02868996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue kallikrein
Description: Intravenous DM199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue kallikrein
Description: Intravenous DM199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue kallikrein
Description: Intravenous DM199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue kallikrein
Description: Intravenous DM199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue kallikrein
Description: Intravenous DM199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue kallikrein
Description: Intravenous DM199
Study: NCT04019054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC)
Description: iTBS delivered to vmPFC for active treatment of spider phobia.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS), vertex
Description: iTBS delivered to vertex for placebo treatment of spider phobia.
Study: NCT04096677

Intervention type: PROCEDURE
Intervention: hysteroscpy
Study: NCT03673982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCASK
Description: Materials and support to aid transitions
Study: NCT01801917

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
Study: NCT03318627

Intervention type: DEVICE
Group type: OTHER
Intervention: Sterile Spring Scale
Description: Measuring intraoperative tension of tendon of rotator cuff tear
Study: NCT00809588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, lethally irradiated melanoma cells
Description: Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
Study: NCT03583294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI pelvic
Description: Pelvic MRI
Study: NCT02932423

Intervention type: OTHER
Group type: OTHER
Intervention: Test product D
Description: Beverage with 47 g/L sugar and sweetener
Study: NCT03583294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI pelvic
Description: Pelvic MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI pelvic
Description: Pelvic MRI
Study: NCT00826137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin and fructo-oligosaccharides.
Description: Supplement during antibiotic treatment+14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is base powder of product with no oligosaccharides.
Study: NCT02932423

Intervention type: OTHER
Group type: OTHER
Intervention: Test product D
Description: Beverage with 47 g/L sugar and sweetener

Intervention type: OTHER
Group type: OTHER
Intervention: Comparative product F
Description: Beverage with 98 g/L sugar

Intervention type: OTHER
Group type: OTHER
Intervention: Comparative product F
Description: Beverage with 98 g/L sugar